Amgen's First EU Biosimilar Filing Targets AbbVie's Humira
This article was originally published in Scrip
Amgen has begun its incursion into the EU biosimilars market by filing an approval application with the European Medicines Agency for ABP 501, a version of AbbVie's blockbuster MAb Humira (adalimumab). This is the company's first biosimilar filing in Europe, and it believes it is also the first EU filing for a biosimilar Humira.
Register for our free email digests: